• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性肾病患者肌肉流失、骨质疏松和血管钙化的三重打击凸显了新型治疗策略的必要性。

[The triple whammy of muscle loss, osteoporosis and vascular calcification in chronic kidney disease patients calls out the need for novel treatment strategies].

作者信息

Jia Ting, Stenvinkel Peter, Lindholm Bengt

出版信息

G Ital Nefrol. 2013 May-Jun;30(3).

PMID:23832479
Abstract

Chronic kidney disease (CKD) is characterized by numerous metabolic, nutritional and cardiovascular complications including loss of muscle mass, osteoporosis and vascular calcification contributing to the high mortality among these patients. Factors involved in the underlying pathology processes resulting in these complications such as insulin-like growth factor-1 system, calcium and phosphate homeostasis, fibrosis growth factor-23/parathyroid hormone pathway, receptor activator of nuclear-factor B system and osteoprotegerin pathway are closely interrelated and may act synergistically. Thus, the regulation of protein degradation, bone loss and vascular calcification share several common mediators and mechanisms, underlining the need for research approaches focusing on these shared mechanisms and pathways. This brief review aims at summarizing advances in our current understanding of the basis for development of muscle loss, osteoporosis and vascular calcification and also the possible connections among them in the CKD patients.

摘要

慢性肾脏病(CKD)的特征是存在众多代谢、营养和心血管并发症,包括肌肉量减少、骨质疏松和血管钙化,这些导致了此类患者的高死亡率。导致这些并发症的潜在病理过程所涉及的因素,如胰岛素样生长因子-1系统、钙和磷稳态、成纤维细胞生长因子-23/甲状旁腺激素途径、核因子κB受体激活剂系统和骨保护素途径,相互密切关联且可能协同作用。因此,蛋白质降解、骨质流失和血管钙化的调节共享几种常见的介质和机制,这突出了专注于这些共享机制和途径的研究方法的必要性。本简要综述旨在总结我们目前对CKD患者肌肉减少、骨质疏松和血管钙化发生基础的理解进展,以及它们之间可能的联系。

相似文献

1
[The triple whammy of muscle loss, osteoporosis and vascular calcification in chronic kidney disease patients calls out the need for novel treatment strategies].慢性肾病患者肌肉流失、骨质疏松和血管钙化的三重打击凸显了新型治疗策略的必要性。
G Ital Nefrol. 2013 May-Jun;30(3).
2
Molecular Mechanisms of Vascular Calcification in Chronic Kidney Disease: The Link between Bone and the Vasculature.慢性肾脏病中血管钙化的分子机制:骨骼与血管系统之间的联系
Curr Osteoporos Rep. 2015 Aug;13(4):206-15. doi: 10.1007/s11914-015-0270-3.
3
[Vascular Calcification - Pathological Mechanism and Clinical Application - . Vascular calcification in chronic kidney disease-mineral and bone disorder (CKD-MBD)].[血管钙化——病理机制与临床应用——. 慢性肾脏病 - 矿物质和骨异常(CKD-MBD)中的血管钙化]
Clin Calcium. 2015 May;25(5):645-53.
4
Mechanistic insights into CKD-MBD-related vascular calcification and its clinical implications.CKD-MBD 相关血管钙化的机制研究及临床意义。
Life Sci. 2022 Dec 15;311(Pt B):121148. doi: 10.1016/j.lfs.2022.121148. Epub 2022 Nov 3.
5
Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.慢性肾脏病中骨矿物质代谢紊乱的整体药理学管理(第一部分):从治疗磷酸盐失衡到控制甲状旁腺激素和预防心血管钙化进展。
Expert Opin Pharmacother. 2016 Jun;17(9):1247-58. doi: 10.1080/14656566.2016.1182155. Epub 2016 May 13.
6
Bone-Vascular Axis in Chronic Kidney Disease.慢性肾脏病中的骨-血管轴。
Adv Chronic Kidney Dis. 2019 Nov;26(6):472-483. doi: 10.1053/j.ackd.2019.09.006.
7
[Role of calcium and phosphate in atherosclerosis and vascular calcification].[钙和磷在动脉粥样硬化及血管钙化中的作用]
Clin Calcium. 2013 Apr;23(4):489-96.
8
Mineral Bone Abnormalities and Vascular Calcifications.矿物质骨骼异常和血管钙化。
Adv Chronic Kidney Dis. 2019 Nov;26(6):409-416. doi: 10.1053/j.ackd.2019.09.004.
9
Vascular calcification in end-stage renal disease patients.终末期肾病患者的血管钙化
Contrib Nephrol. 2015;185:156-67. doi: 10.1159/000380980. Epub 2015 May 19.
10
Vascular calcification in chronic kidney disease.慢性肾脏病中的血管钙化
J Bone Miner Metab. 2006;24(2):176-81. doi: 10.1007/s00774-005-0668-6.